The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A translational study to evaluate genomic markers and concordance with circulating-tumor DNA and circulating tumor cells to predict clinical outcomes in gastrointestinal and pancreatobiliary cancers: Valor trial.
 
Ayako Doi
No Relationships to Disclose
 
Kumiko Umemoto
No Relationships to Disclose
 
Tomoyo Oguri
No Relationships to Disclose
 
Hiroyuki Takeda
No Relationships to Disclose
 
Yoshiki Horie
No Relationships to Disclose
 
Takashi Ogura
No Relationships to Disclose
 
Takuro Mizukami
Honoraria - Asahi Kasei; Lilly Japan; Merck; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Naoki Izawa
Speakers' Bureau - Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Sungmok Jung
Employment - Clinomics
Stock and Other Ownership Interests - Clinomics
Research Funding - Clinomics
Travel, Accommodations, Expenses - Clinomics
Other Relationship - Clinomics
 
Byung Chul Kim
Employment - Clinomics
Leadership - Clinomics
Stock and Other Ownership Interests - Clinomics
Honoraria - Clinomics
Research Funding - Clinomics
Travel, Accommodations, Expenses - Clinomics
Other Relationship - Clinomics
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Takeda
Research Funding - Chugai Pharma; Daiichi Sankyo (Inst); Lilly Japan (Inst); Sanofi; Taiho Pharmaceutical; Takeda (Inst)